Antitrust Defense in Healthcare Serial Roll-Up Acquisitions
Strategic navigation of FTC, DOJ, and state-level healthcare merger oversight following federal enforcement actions targeting private equity physician consolidations.
Federal antitrust regulators (FTC and DOJ) and state attorneys general have placed private equity healthcare roll-ups under intense scrutiny. Following high-profile enforcement actions like the FTC challenge against U.S. Anesthesia Partners (USAP) in Texas, regulators are actively targeting 'serial acquisitions'—a strategy where multiple small, sub-Hart-Scott-Rodino (HSR) transactions cumulatively create regional market power. Kompanie LLP guides private equity sponsors in designing non-monopolistic roll-up theses: building multi-specialty clinical hubs rather than single-specialty monopolies, maintaining patient choice, documenting consumer price benefits, and preparing for evolving state pre-closing notification statutes (California, Texas, New York).
Deliverables
- Herfindahl-Hirschman Index (HHI) geographic market concentration modeling for target acquisitions.
- Multi-specialty clinical diversification strategy to avoid single-specialty dominance thresholds.
- State-level healthcare transaction notification and compliance audit (evaluating 30-day to 90-day waiting periods).
- Pro-competitive clinical integration documentation demonstrating improved patient access and lower out-of-pocket costs.
Frequently asked questions
How did the USAP Texas antitrust case change the landscape for PE physician roll-ups?
The USAP litigation established that the FTC will challenge cumulative roll-ups under Section 7 of the Clayton Act and Section 2 of the Sherman Act, even if individual practice acquisitions were far below HSR filing thresholds. Platforms must now demonstrate that consolidation creates genuine clinical integration rather than price leverage over payers.
What strategies protect an MSO platform from antitrust enforcement?
Diversifying across complementary specialties (e.g. combining primary care, endocrinology, and sports medicine rather than acquiring all local cardiologists), expanding into underserved suburban sub-markets, and demonstrating shorter patient wait times and superior clinical quality metrics.